Siemens chooses ONCOlog Medical DIGNITY Carrier for PET/CT

Press release
Stockholm, January 29, 2010


Siemens chooses ONCOlog Medical DIGNITY Carrier for PET/CT

LinkMed's portfolio company has received an order from Siemens AG, Health Care
Sector, Germany for its patient transportation solution, DIGNITY™ Carrier, for
setting up patients for PET/CT imaging for special applications.

The first installation with the unique solution of smooth transportation of
patients, from set up and/or treatment rooms to PET/CT room, will be done at the
Particle Therapy Centre at the University of Heidelberg in Germany during spring
2010. The order includes a special adaption of the DIGNITY™ Carrier to allow
smooth docking to the Siemens PET/CT.

In particle therapy PET imaging is a non-invasive way of in vivo verification of
the dose delivered to the target volume, by monitoring induced radiation from
positron emitting isotopes such as 11C and 15O. 

The degradation of activity (half-life for 11C is twenty minutes and for 15O two
minutes) requires that the irradiated patient must be moved for PET imaging in a
very short time. This has up till now been very difficult without changing the
patient´s geometrical set up conditions.

With the ONCOlog Medical DIGNITY™ Carrier, the irradiated patient can be
transported in treatment position to PET imaging fast and smoothly.

“We are very excited about this strategic order from the Siemen's PET division.
We foresee from now on a new market segment for accurate in vivo dose
verification after high energy radiotherapy, where ONCOlog Medical can become
one of the leading companies”, says Hans Dahlin, CEO of ONCOlog Medical.

Read more about ONCOlog Medical at www.oncologmedical.com.

For more information please contact:
Hans Dahlin, CEO ONCOlog Medical QA AB: +46 18 19 45 63
Lars Martin, VP Senior Venture Manager LinkMed AB: +46 706 360219


LinkMed develops life science companies in collaboration with innovators and
other financiers. By contributing management and capital, LinkMed has created a
portfolio of thirteen companies, four in drug development and biotechnology and
nine in diagnostics and medical technology. The company's principal shareholders
are Mohammed Al Amoudi, FastPartner AB (publ), and Mannersons Fastighets AB.
LinkMed is listed on the NASDAQ OMX Stockholm Exchange in the Small Cap section
(ticker: LMED).